Abstract
The high-affinity binding sites for [3H]-imipramine (IMI) present in human platelets are associated with the neuronal uptake system for 5HT. It was recently demonstrated that previous antidepressant therapy with drugs which inhibit 5HT uptake could down-regulate [3H]-IMI binding and that this effect could persist up to 1 month after the end of treatment. We therefore re-examined the reported differences inB max of [3H]-IMI binding in platelets between control and depressed untreated patients, to evaluate the residual influence of previous antidepressant medication. The saturation characteristics of [3H]-IMI binding were compared in platelets from 17 depressed patients care-fully selected according to previous antidepressant therapy and washout period, who were closely matched, for age and sex, with a group of control healthy volunteers. The results reveal a significant decrease by 47% in theB max of [3H]-IMI binding in platelets of untreated depressed patients when compared with controls. There was no significant modification ofK d values for platelet [3H]-IMI binding between the depressed and the control groups. Our results support the view that platelet [3H]-IMI binding is a useful tool as a biological marker in depression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Angel I, Paul SM (1984) Inhibition of synaptosomal 5-[3H]hydroxytryptamine uptake by endogenous factor(s) in human blood. FEBS Lett 171: 280–284
Asarch KB, Shih JC, Kulcsar A (1980) Decreased3H-imipramine binding in depressed males and females. Commun Psychopharmacol 4: 425–432
Barbaccia ML, Gandolfi O, Chuang DM, Costa E (1983) Modulation of neuronal serotonin uptake by a putative endogenous ligand of imipramine binding sites. Proc Natl Acad Sci 80: 5134–5138
Baron M, Barkai A, Gruen R, Kowalik S, Quitkin F (1983)3H-Imipramine platelet binding sites in unipolar depression. Biol Psychiatry 18: 1403–1409
Braddock LE, Cowen PJ, Eliott JM, Fraser S, Stump K (1984) [3H]-yohimbine in normal subjects taking amitriptyline. Neuropharmacology 23: 285–286
Briley M, Langer SZ, Raisman R, Sechter D, Zarifian E (1980) Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science 209: 303–305
Brusov OS, Fomenko AM, Katasonov AB (1985) Human plasma inhibitors of platelet serotonin uptake and imipramine receptor binding: extraction and heterogeneity. Biol Psychiatry 20: 235–244
Egrise D, Desmedt D, Schoutens A, Mendlewicz J (1983) Circannual variations in the density of tritiated imipramine binding sites on blood platelets in man. Neuropsychobiology 10: 101–102
Hrdina PD (1984)3H-Imipramine binding sites in brain downregulated by chronic nortriptyline and haloperidol but not mianserin treatment. Psychiatr Res 11: 271–278
Kinnier WJ, Chuang DM, Costa E (1980) Down regulation of dihydroalprenolol and imipramine binding sites in brain of rats repeatedly treated with imipramine. Eur J Pharmacol 67: 289–294
Langer SZ, Briley MS, Raisman R, Henry JF, Morselli PL (1980) Specific3H-imipramine binding in human platelets: influence of age and sex. Naunyn-Schmiedeberg's Arch Pharmacol 313: 189–194
Langer SZ, Zarifian E, Briley MS, Raisman R, Sechter D (1981) High-affinity binding of3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders. Life Sci 29: 211–218
Langer SZ, Raisman R, Sechter D, Gay C, Loo H, Zarifian E (1984a) H-Imipramine and3H-desipramine binding sites in depression. In: Usdin E et al. (eds) Frontiers in biochemical and pharmacological research in depression. Raven Press, New York, pp 113–125
Langer SZ, Raisman R, Tahraoui L, Scatton B, Niddam R, Lee CR, Claustre Y (1984b) Substituted tetrahydro-β-carbolines are possible candidates as endogenous ligand of the [3H]imipramine recognition site. Eur J Pharmacol 98: 153–154
Langer SZ, Sechter D, Loo H, Raisman R, Zarifian E (1986) Electroconvulsive shock therapy andB max of platelet3H-imipramine binding in depression. Arch Gen Psychiatry (in press)
Lewis DA, McChesney C (1985) Tritiated imipramine binding distinguishes among subtypes of depression. Arch Gen Psychiatry 42: 485–488
Mellerup ET, Plenge P, Rosenberg R (1982)3H-Imipramine binding sites in platelets from psychiatric patients. Psychiatr Res 7: 221–227
Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK (1981) Depressed patients have decreased binding of tritiated imipramine to platelet serotonin transporter. Arch Gen Psychiatry 38: 1315–1317
Perry EK, Marshall EF, Blessed G, Tomlinson BE, Perry RH (1983) Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry 142: 188–192
Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83: 346
Plenge P, Mellerup ET (1982)3H-Imipramine high-affinity binding sites in rat brain. Effects of imipramine and lithium. Psychopharmacology 77: 94–97
Poirier MF, Loo H, Benkelfat C, Sechter D, Zarifian E, Galzin AM, Schoemaker H, Segonzac A, Langer SZ (1984) [3H]-Imipramine binding and [3H]-5HT uptake in human blood platelets: changes after one week chlorimipramine treatment. Eur J Pharmacol 106: 629–633
Raisman R, Briley M, Langer SZ (1980) Specific tricyclic antidepressant binding sites in rat brain characterized by high affinity3H-imipramine binding. Eur J Pharmacol 61: 373–380
Raisman R, Sechter D, Briley MS, Zarifian E, Langer SZ (1981) High affinity3H-imipramine binding in platelets from untreated and treated depressed patients compared to healthy volunteers. Psychopharmacology 75: 368–371
Raisman R, Briley MS, Bouchami F, Sechter D, Zarifian E, Langer SZ (1982)3H-Imipramine binding and serotonin uptake in platelets from untreated depressed patients and control volunteers. Psychopharmacology 77: 332–335
Rehavi M, Ventura I, Sarne Y (1985) Demonstration of endogenous “imipramine-like” material in rat brain. Life Sci 36: 686–693
Segonzac A, Schoemaker H, Tateishi T, Langer SZ (1985) 5-MeO-tryptoline, a competitive endocoid acting at3H-imipramine recognition sites in human platelets. J Neurochem 45: 249–256
Suranyi-Cadotte BE, Wood PL, Nair NPV, Schwartz G (1982) Normalization of platelet [3H]-imipramine binding in depressed patients during remission. Eur J Pharmacol 85: 357–358
Suranyi-Cadotte BE, Quirion R, Nair NPV, Lafaille F, Schwartz G (1984) Effect of antidepressant administration on serotonin uptake and3H-imipramine binding sites in platelets from depressed and normal subjects. Proceedings of the Congress for Neurosciences Los Angeles, p 289
Suranyi-Cadotte BE, Quirion R, Nair NPV, Lafaille F, Schwartz G (1985) Imipramine treatment differentially affects platelet3H-imipramine binding and serotonin uptake in depressed patients. Life Sci 36: 795–799
Whitaker PM, Warsh JJ, Stancer HC, Persad E, Vint CK (1984) Seasonal variation in platelet3H-imipramine binding: comparable values in control and depressed populations. Psychiatr Res 11: 127–131
Wood PL, Suranyi-Cadotte BE, Schwartz G, Nair NPV (1983) Platelet3H-imipramine binding and red blood cell choline in affective disorders: indications of heterogeneous pathogenesis. Biol Psychiatry 18: 715–719
Zsilla G, Barbaccia ML, Gandolfi O, Knoll J, Costa E (1983) (−)-Deprenyl a selective MAO “B” inhibitor increases [3H]-imipramine binding and decreases β-adrenergic receptor function. Eur J Pharmacol 89: 111–117
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Poirier, MF., Benkelfat, C., Loo, H. et al. Reduced Bmax of [3H]-imipramine binding to platelets of depressed patients free of previous medication with 5HT uptake inhibitors. Psychopharmacology 89, 456–461 (1986). https://doi.org/10.1007/BF02412121
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02412121